 |
|
Risk of Tardive Dyskinesia in Older PatientsA Prospective Longitudinal Study of 266 Outpatients
Dilip V. Jeste, MD;
Michael P. Caligiuri, PhD;
Jane S. Paulsen, PhD;
Robert K. Heaton, PhD;
Jonathan P. Lacro, PharmD;
M. Jackuelyn Harris, MD;
Anne Bailey, MS;
Robert L. Fell, MS;
Lou Ann McAdams, PhD
Arch Gen Psychiatry. 1995;52(9):756-765.
Abstract
Background
Neuroleptic-induced tardive dyskinesia (TD) is a major iatrogenic disorder that is more prevalent among older patients. The objective of this study was to determine the incidence of and risk factors for TD in neuroleptic-treated patients over age 45 years.
Methods
We studied 266 middle-aged and elderly outpatients with a median duration of 21 days of total lifetime neuroleptic exposure at study entry. Most patients were treated throughout the study with either a high-potency or a low-potency neuroleptic and maintained on relatively low doses. The patients were followed up at 1- to 3-month intervals with "blind" assessment of psychopathologic condition, clinically as well as instrumentally (ie, using electromechanical sensors with computerized data reduction, including spectral analysis) evaluated movement disorder, and global cognitive function.
Results
Cumulative incidence of TD was 26%, 52%, and 60% after 1,2, and 3 years, respectively. The principal risk factors for TD were duration of prior neuroleptic use at baseline, cumulative amount of high-potency neuroleptics, history of alcohol abuse/dependence, borderline or minimal dyskinesia, and tremor on instrumental assessment.
Conclusion
Use of higher amounts of neuroleptics, particularly high-potency ones, should be avoided in older patients, patients with alcohol abuse/dependence, or patients with a subtle movement disorder at baseline; these patients are at a higher risk of developing TD.
Author Affiliations
From the Department of Psychiatry, University of California, San Diego (Drs Jeste, Caligiuri, Paulsen, Heaton, Lacro, Harris, and McAdams, Ms Bailey, and Mr Fell), and San Diego Veterans Affairs Medical Center (Drs Jeste, Caligiuri, Paulsen, Lacro, and Harris).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis
Uchida et al.
Schizophr Bull 2011;37:788-799.
ABSTRACT
| FULL TEXT
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck
Br. J. Psychiatry 2007;191:238-245.
ABSTRACT
| FULL TEXT
The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England
Twaites et al.
J Psychopharmacol 2007;21:392-399.
ABSTRACT
The relationship between patient satisfaction and treatment outcomes in schizophrenia
Chue
J Psychopharmacol 2006;20:38-56.
ABSTRACT
Atypical Antipsychotics: Impact on Overall Health and Quality of Life
Boyd
J Am Psychiatr Nurses Assoc 2002;8:S9-S17.
ABSTRACT
A 23-Year-Old Man With Schizophrenia
Goff
JAMA 2002;287:3249-3257.
FULL TEXT
Use of atypical antipsychotic drugs in old age psychiatry
Bouman and Pinner
Adv. Psychiatr. Treat. 2002;8:49-58.
FULL TEXT
The Current Status of Tardive Dyskinesia
Sachdev
Aust N Z J Psychiatry 2000;34:355-369.
ABSTRACT
| FULL TEXT
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
De Deyn et al.
Neurology 1999;53:946-946.
ABSTRACT
| FULL TEXT
Early Intervention in Schizophrenia in the Elderly
Burke and Shome
Aust N Z J Psychiatry 1998;32:809-814.
ABSTRACT
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos et al.
Arch Gen Psychiatry 1996;53:313-319.
ABSTRACT
|
